Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

GlaxoSmithKline Pharmaceuticals on Friday said its consolidated net profit increased 12 per cent year-on-year to Rs 279 crore ...

GlaxoSmithKline ( ($GSK) ) has released its Q2 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...

Glaxo (GSK) delivered earnings and revenue surprises of +9.82% and +3.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, boosting globalization for Hengrui and expanding GSK's oncology and RI&I pipeline.